TheEdgeResearch
Home / Stocks / BOVNF

BioInvent International AB (publ) (BOVNF)

OTC Healthcare Biotechnology
$3.29 ▲ +0.00%
Market Cap
$216.4M
Sector
Healthcare
Industry
Biotechnology
Beta
0.02
52-Wk Range
3.2886-4.7
CEO
Martin Welschof
Country
SE
Currency
USD

BioInvent International AB (publ) operates in the Biotechnology industry of the Healthcare sector, headquartered in Lund, SN, SE. The stock last traded at $3.29, up 0.00% on the session, giving a market capitalisation of $216.4M. On trailing twelve-month figures it carries a trailing P/E of -4.68, a net margin of -154.0%. Its beta of 0.02 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-4.68
Price / Sales
7.19
Price / Book
3.57
EV / EBITDA
-3.72
Gross margin
98.5%
Operating margin
-161.0%
Net margin
-154.0%
Return on equity
Debt / equity
0.01
Current ratio
5.32
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
109
IPO date
2013-09-03
Headquarters
Lund, SN, SE
About BioInvent International AB (publ)

BioInvent International AB (publ) is a clinical-stage biotechnology company primarily focused on identifying, exploring, and engineering immunomodulatory antibodies to combat various forms of cancer. The company's activities extend globally, reaching markets in Sweden, across Europe, the United States, Japan, and other international regions. Its leading investigational compound is BI-1206, which is being developed to address both non-Hodgkin lymphoma and a range of solid tumors. Beyond this flagship program, BioInvent is advancing a diverse pipeline of therapeutic candidates. These include agents designed to target tumor-associated myeloid cells and cancer-associated regulatory T cells, which play a vital role in regulating the immune system. The company's portfolio also features BT-001 for solid tumor indications, as well as BI-1808 and BI-1910 – both anti-TNFR2 antibodies specifically intended for the treatment of solid tumors and cutaneous T-cell lymphoma. To further its development initiatives, BioInvent has established several key collaborations. It maintains a strategic alliance with Pfizer Inc. for the development of antibodies targeting tumor-associated myeloid cells. The company also collaborates with Transgene to jointly create innovative multi-functional oncolytic viruses aimed at solid tumors. Additionally, a collaboration and supply agreement with Merck facilitates the clinical advancement of BI-1808. Founded in 1996, BioInvent International AB (publ) maintains its headquarters in Lund, Sweden.

Comparable companies

BioInvent International AB (publ) is most often compared with the following Healthcare names:

AVCTFCLVLYCYDYGSGTFHLOSFMDCLFNWBOPRRUFPTCHFRAONF
More research on BOVNF
BOVNF technical analysis BOVNF TheEdge Score Compare against peers
Open full interactive analysis & DCF →